Amendments to the Pharmaceutical Affairs Act to Strengthen Administrative & Criminal Sanctions for Data Manipulation Related to Applications for Regulatory Approvals
On April 7, 2020, an amendment to the Pharmaceutical Affairs Act (the 'PAA') came into effect to provide a statutory basis for administrative and criminal sanctions to be enforced against companies that have obtained regulatory approval for a drug product through deceitful or otherwise improper means.
May 5, 2020
1. Amendment to the Pharmaceutical Affairs Act
Recently, multiple big pharmaceutical companies in Korea were found to have obtained regulatory approval for a drug product based on false or manipulated data. Yet, there was no statutory basis under the PAA to directly sanction such pharmaceutical companies for data manipulation. To address this legislative gap, the new PAA amendment established provisions based on which administrative sanctions and criminal penalties could be directly imposed on companies that obtained regulatory approval under the PAA through deceitful or otherwise improper means. The main details of the amendment are set out below:
Based on the interpretation of 'deceitful' and 'improper' means that were at issue under a different law in a Supreme Court case precedent, this new amendment would not only be applicable to simple data manipulation, but is also expected to be more broadly applicable to an action or inaction, which is deemed fraudulent or otherwise unfair by social norms, that can affect the decision-making of regulatory authorities granting regulatory approval when such approval otherwise could not have been granted.
2. Other efforts by MFDS to strengthen regulations on data manipulation
Further, based on the official press release by the Ministry of Food and Drug Safety (the 'MFDS') on April 17, 2020, it appears that the MFDS is pursuing systemic and legal improvements with respect to data manipulation regulation through the following.
(1) Strengthen the MFDS' GMP compliance oversight by introducing a system that can track and verify the history of changes made, such as modification, deletion, and addition of data during the manufacturing and quality management of pharmaceutical products, for types of data that are more susceptible to manipulation (e.g., handwritings and pictures); and
(2) Push for amendment of the PAA to enhance punitive fines and administrative sanctions against companies that have obtained economic benefits through data manipulation, and reject applications for marketing approval of such companies for a prescribed period of time.
The PAA amendment is expected to become an important stepping stone for Korean regulatory and investigative agencies to strictly evaluate and enforce pharmaceutical data integrity. In fact, in response to the recent pharma data manipulation case, not only have strong criminal measures been imposed, such as company search and seizure and the arrest of persons involved, but penalties which severely affect the business, such as cancellation of marketing approval for the relevant product item, have also been imposed.
Therefore, a thorough verification of data integrity with respect to its submitted materials would be needed for any company that wishes to obtain regulatory approvals for a drug product (i.e., marketing approval, IND, etc.) in Korea. In addition, it would be necessary to regularly conduct compliance due diligence (i.e., mock inspections) of Korean offices and business sites in preparation for strengthened criminal investigations. A response manual should also be established for the company to rely on should the company be faced with a problematic situation. More importantly, in the event a problem occurs, it is crucial to engage competent legal counsel immediately to receive assistance during the investigation procedures and administration investigations.
Items You Might Have Missed
New KBLA Tools for Business Warriors
One of the driving goals of KBLA in 2020 is to create and offer new tools to aid each member of the KBLA community in accomplishing their business goals.
We have a list of new, exploratory tools to bring out over the course of the year, all of which fall into one or more of three categories that mesh with the KBLA’s overall mission.
Oct. 29, 2019
A New KBLA for 2020
There are many changes coming to KBLA in 2020. We hope you’ll stay with us and experience all we have lined up. We think this is going to be the best iteration yet. Joining KBLA is a chance to support real change among business communities in Korea.
Nov. 19, 2019
Why Does KBLA Exist?
Korea needs foreign participation in the domestic economy like never before.
The world is changing and Korea is changing. Korea has new and existing challenges in rapidly weakening demographics, highly concentrated market structure, increasing protectionism, rising export similarity among competitors, low productivity growth, low domestic investment levels, and the rising importance of services. Most, if not all, of these things can be overcome through increased participation of the global business community in the Korean economy.
Nov. 24, 2019
It’s 2020, Do You Know Where Your Meeting Attendees Are?
We know one thing: they are not at your meeting. That’s because in-person meetings aren’t what they once were: the only game in town. In 2020, along the curve of value for cost, meetings are are not just at the low end, they are downright abysmal.
Dec. 24, 2019
Act on Online Investment–Linked Financing and User Protection (aka P2P Financing Act) Promulgated on November 26, 2019
The Act on Online Investment–Linked Financing and User Protection (the P2P Financing Act) passed the plenary session of the Korean National Assembly on October 30, 2019 and was promulgated on November 26, 2019.
Jan. 8, 2020